Our website lists jobs from 1193 biotech startups.
| Company (click to see more info) | Short description | Founded | Location | Clinical stage | Therapy area | Drug types | Drug notes | Funding | Investors |
|---|---|---|---|---|---|---|---|---|---|
| 1. 1910 Genetics | Computational chemistry platform to develop small molecule therapeutics | 2018 | Boston, MA | RD | Neurological conditions | NEU, INF, IMM, ONC, RAR, GEN | Undisclosed programs RD infectious diseases, immunology conditions, oncology, rare & genetic diseases | $22M A Mar 2021; $4.1M Seed | FoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital, M12 |
| 2. 20n Bio | Computational Synthetic Biology | 2021 | Malvern, PA | $3.3M seed Dec 2021 | BlueRun Ventures China | ||||
| 3. 3DBio Therapeutics | Therapeutic-grade Bioprinting | 2014 | Long Island City, NY | $5.3M A Apr 2021 | |||||
| 4. 3T Biosciences | TCR Therapies | 2017 | South SF, CA | RD | Solid tumors | ONC, IMM, VAC, INF | Undisclosed programs RD autoimmune diseases, viral infections | $40M A Aug 2022; $12M seed Oct 2017 | Westlake Village BioPartners, Lightspeed Venture Partners |
| 5. 4D Molecular Therapeutics | Gene Therapy | 2013 | Emeryville, CA | Clin1/Clin2 | Fabry disease | GEN, OPH, RAR, LNG, GER, CVV | 4D-150 Clin1/Clin2 wet AMD, Clin0 DME; 4D-125 Clin1/Clin2 XLRP; 4D-110 Clin1/Clin2 choroideremia; 4D-710 Clin1/Clin2 cystic fibrosis, additional effort Clin0 cystic fibrosis; 4D-175 RD geographic atrophy; 4D-725 RD A1AT deficiency; undisclosed RD eye disease | $138M stock May 2023; $222M IPO Dec 2020; $75M Jun 2020; $90M B Sep 2018; $20M prior | |
| 6. 64x Bio | High throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics | 2018 | San Francisco, CA | $55M A Jan 2022 | |||||
| 7. 76Bio | Targeted Protein Degraders | 2020 | Boston, MA | RD | Undisclosed | ||||
| 8. A-Alpha Bio | Yeast-based Drug Assay | 2017 | Seattle, WA | $22.4M A2 Jul 2023; $20M A Sep 2021; $2.8M seed Sep 2019; $225 NSF grant Jul 2018 | |||||
| 9. A2 Biotherapeutics | Immunotherapy | 2017 | Agoura Hills, CA | Clin1 | Multiple cancers | ONC | A2B694 Clin0 multiple cancers; 3 undisclosed programs RD undisclosed | $71.5M B Oct 2020; $57M A Nov 2019 | |
| 10. AAVogen | Gene therapeutics to strengthen muscle and fight disease | 2015 | Rockville, Maryland | Clin0 | Inclusion body myositis | MUS, NWL, GEN | Also Clin0 cancer cachexia, RD DMD | <10M | |
| 11. ACELYRIN | Antibody Mimetic | Agoura Hills, CA | Clin3 | Uveitis | OPH, IMM, RHU, DRM | Also Clin3 hidradenitis suppurativa, Cin3 psoriatic arthritis, Clin2 axial spondyloarthritis; Lonigutamab Clin1 thyroid eye disease; XLRN-517 Clin0 urticaria | |||
| 12. AI Proteins | |||||||||
| 13. AIRNA Bio | RNA Editing Therapeutics | Cambridge, MA | RD | Alpha-1 antitrypsin deficiency | RAR, GEN | Also RD undisclosed | |||
| 14. ALX Oncology | Immuno-oncology | 2015 | South SF, CA | Clin2 (fast track) | Head & neck cancer (partner: Merck) | ONC | Also different combo Clin2 (fast track) head & neck cancer (partner: MercK), Clin2 (fast track) gastric cancer (partner: Lilly), Clin1 urothelial cancer; 2 trials Clin1 breast cancer (one partnered: Zymeworks), Clin0 multiple myeloma; ALTA-002 Clin0 oncology | $185.7M IPO Jul 2020; $105M C Feb 2020; $36M A Mar 2015 | |
| 15. AN2 Therapeutics | Novel medicines targeting infectious diseases | 2019 | Menlo Park, CA | Clin1 | NTM lung disease | INF | Also 2 additional efforts Clin0/Clin1 NTM lung diseases, Clin0 melioidosis | $70M stock Aug 2023; $79.4M IPO Mar 2022; $80M B Jan 2022; $12M A Nov 2019 | |
| 16. AOA Dx | Cancer Diagnosis | 2020 | Boulder, CO | $7M Seed Sep 2022 | Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent | ||||
| 17. ARTBIO | Radioligand therapy | Oslo, Norway | Clin0 | Prostate Cancer | ONC | ABA RD solid tumors; ABB RD solid tumors | |||
| 18. AS2 Bio Inc | |||||||||
| 19. AUM BioTech | RNA-silencing Products | 2015 | Philadelphia, PA | ||||||
| 20. AVROBIO | Cellular & Gene Therapies | 2016 | Cambridge, MA | Clin1/Clin2 | Gaucher disease type 1 | RAR, GEN, PED | Also Clin0 Gaucher disease type 3; AVR-RD-04 Clin1/Clin2 cystinosis; AVR-RD-05 Clin0 Hunter syndrome; AVR-RD-03 Clin0 Pompe disease | $100M IPO Feb 2020 | |
| 21. Ab Studio | Antibody humanization and optimization service | 2017 | Hayward, CA | ||||||
| 22. Abalone Bio | Antibody Therapies | 2017 | Emeryville , CA | Clin0 | Diabetic peripheral neuropathic pain | PN, LNG, INF, HEP, GI, ONC, NPH, END, NWL | Undisclosed Clin0 liver fibrosis/NASH; undisclosed Clin0 lung conditions/influenza; undisclosed Clin0 IBD; 5 undisclosed programs RD immuno-oncology, polycystic kidney disease, obesity, diabetes | ||
| 23. Abata Therapeutics | Treg Cell Therapies | 2021 | Cambridge, MA | Clin0 | MS | IMM, NEU, END, MUS | Undisclosed programs RD diabetes (1), RD inclusion body myositis | $95M A Jun 2021 | |
| 24. Abeona Therapeutics | Therapies for Sanfilippo (SF) Syndrome Type A and Type B. | 2013 | Cleveland, OH | Clin3 (fast track) | Recessive dystrophic epidermolysis bullosa (ODD) | GEN, DRM, PED, RAR, OPH | AB0-504 RD/Clin0 Stargardt disease; ABO-503 RD/Clin0 x-linked retinoschisis; ABO-505 RD/Clin0 autosomal dominant optic atrophy; AIM Vectors RD undisclosed | $25M stock Jul 2023; $35M stock Nov 2022; $25M stock Apr 2022 | |
| 25. Abintus Bio | Gene Therapy | 2020 | San Diego, CA | Clin0 | Lymphomas | ONC, INF | 3 undisclosed programs RD oncology, infectious disease, undisclosed | ||
| 26. Abiosciences | |||||||||
| 27. Absci | |||||||||
| 28. Accelevir Diagnostics | |||||||||
| 29. Accent Therapeutics | RNA-modifying protein inhibitors | Lexington, MA | Clin0 | Multiple cancers | ONC | 3 additional undisclosed programs RD/Clin0 multiple cancers; undisclosed programs RD undisclosed | |||
| 30. Acepodia | Antibody-Cell Conjugation Therapy | Alameda, CA | Clin1 | Solid tumors (partner: JW Therapeutics) | ONC | ACE1831 Clin1 hematological cancers; ACE2016 Clin0 oncology; ACE1708 RD solid tumors | |||
| 31. Achieve Life Sciences | Small Molecules | Bothell, WA | Clin3 | Smoking cessation | ABU | Also 2 additional trials Clin2/Clin3 smoking cessation, Clin2 e-cigarette cessation | |||
| 32. Acomhal Research | 2017 | Roanoke, Virginia | <10M | ||||||
| 33. Acrivon Therapeutics | Checkpoint Inhibitor | Watertown, MA | Clin2 (fast track) | Ovarian cancer | ONC | Also Clin2 (fast track) endometrial cancer, Clin2 bladder cancer, 3 combo trials Clin2 multiple cancers; ACR-2316 RD/Clin0 oncology; 2 undisclosed programs RD oncology, undisclosed | |||
| 34. Actym Therapeutics, Inc. | Microbial-based immunotherapy platform | 2017 | Berkeley, California | Clin0 | Oncology | ONC | 2 undisclosed programs RD oncology | 10 - 100M | |
| 35. Acutis Diagnostics | |||||||||
| 36. Adaptive Phage Therapeutics | |||||||||
| 37. Adcentrx Therapeutics | Antibody drug conjugate | San Diego, CA | Clin1 | Solid tumors | ONC | ADRX-0405 Clin0 oncology; ADRX134 RD oncology; undisclosed programs RD oncology | |||
| 38. Adicet Bio | Immunotherapies | Redwood City, CA | Clin1 | Non-Hodgkin's lymphoma, Lupus (FT) | ONC | ADI-270 Clin0 renal cell carcinoma; ADI-925 Clin0 multiple cancers; ADI-002 Clin0 hepatocellular carcinoma; 3 undisclosed programs RD/Clin0 multiple cancers | |||
| 39. Adiso Therapeutics | |||||||||
| 40. Aditum Bio | |||||||||
| 41. Admera Health | |||||||||
| 42. Adverum Biotechnologies | Adeno-Associated Virus Delivery, Gene Therapy | Redwood City, CA | Clin2 | Wet AMD | OPH, GER, GEN, NEU | Also additional Clin1 wet AMD; undisclosed (partner: GenSight) Clin2 retinitis pigmentosa; undisclosed (partner: Lexeo) Clin1 Friedreich's ataxia; ADVM-062 Clin0 blue cone monochromatism; 4 undisclosed programs RD/Clin0 geographic atrophy, retinitis pigmentosa | |||
| 43. Aeglea BioTherapeutics | |||||||||
| 44. Aera Therapeutics | |||||||||
| 45. Aether Bio | |||||||||
| 46. Affini-T Therapeutics | TCR Cell Therapy | Watertown, MA | Clin0 | Oncology | ONC | AFNT-211 Clin0 oncology; AFNT-212 Clin0 oncology; 4 undisclosed programs RD/Clin0 oncology | |||
| 47. Affinia Therapeutics | Gene Delivery | Waltham, MA | RD | Muscle diseases | GEN, NEU, MUS, CVV, LNG | Additional undisclosed programs RD CNS diseases, cardiac conditions, genetic diseases, cystic fibrosis | |||
| 48. Affinivax | |||||||||
| 49. AgBiome | |||||||||
| 50. Agastiya Biotech | Small Molecules | 2019 | Temecula, California | Clin3 | Psoriasis | DRM, IMM, ONC, END, INF | AB001 Clin2 solid tumors; ABREV01 Clin0 oncology; ABSGM003 RD/Clin0 diabetes; ABCIRT RD/Clin0 undisclosed; ABVIRO RD/Clin0 Dengue, COVID-19 | not disclosed |